In 2019, T3D Therapeutics was awarded the first increment of what could be a $9M grant from National Institutes for Aging to fund Phase II clinical trial for the firm's leading candidate, T3D-959, an orally administered daily treatment for Alzheimers. T3D has an exclusive, worldwide license for T3D-959 and structurally-related molecules -- an optimal therapeutic for the treatment of Alzheimers Disease (AD). TT3D-959 has advanced successfully through Phase 1 human clinical trials showing evidence of pharmacological activity and no reported safety concerns. This drug has the potential to be a transformational therapy by acting in a multi-faceted manner to improve most of the defects (pathologies) of AD, including a likely trigger for the disease, insulin and IGF-resistance. This potential disease-modifying therapeutic is an orally-delivered, once a day medicine for AD patients with mild to moderate disease severity and potentially patients with mild cognitive impairment (MCI). Additionally, the mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) disorders. The Companys vision is to develop the product through a series of three stage gates culminating in a Phase 2b clinical trial. Each stage gate provides a potential opportunity for an investor exit through sale or out-licensing of T3D-959 to a large pharmaceutical company. Development is executed in a capital-efficient, virtual operation that minimizes infrastructure and personnel costs.
